Lung Non-Small Cell Carcinoma

The mutation at codon 3435 (C>T) correlated with a significantly higher response rate to platinum-based chemotherapy in patients with advanced non small cell lung cancer (NSCLC). 103 Chinese patients… (full text at CIViC)

PMID 22296372 · Yan et al., 2011 · Open in CIViC

mRNA expression of ABCB1 in 17 NSCLC cell lines was associated with decreased response to paclitaxel (correlation of mRNA expression and paclitaxel IC50: r=0.5322, P=0.0279).

PMID 21883677 · Meng et al., 2011 · Open in CIViC

Increased expression of ABCC10 in 17 NSCLC cell lines was inversely correlated with paclitaxel sensitivity (r = 0.574; P < 0.05).

PMID 18445659 · Oguri et al., 2008 · Open in CIViC

In this in vitro study, the H2110 non-small cell lung cancer cell line (heterozygous for a G340L mutation) was shown to be susceptible to imatinib and dasatinib monotherapies. This line showed a signi… (full text at CIViC)

PMID 26758680 · Testoni et al., 2016 · Open in CIViC

In this in vitro study, the H1915 non-small cell lung cancer cell line (homozygous for a R351W mutation) was shown to be susceptible to dasatinib. This line showed a significant reduction in colony fo… (full text at CIViC)

PMID 26758680 · Testoni et al., 2016 · Open in CIViC

In this in vitro study, the H1915 non-small cell lung cancer cell line (homozygous for a R351W mutation) was shown to be susceptible to imatinib. This line showed a significant reduction in colony for… (full text at CIViC)

PMID 26758680 · Testoni et al., 2016 · Open in CIViC

Four lung adenocarcinoma cell lines were studied with mutations in ABL1 or ABL2. Sensitivity to imatinib or dasatinib treatment was measured by reduction in colony formation in response to treatment. … (full text at CIViC)

PMID 26758680 · Testoni et al., 2016 · Open in CIViC

Four lung adenocarcinoma cell lines were studied with mutations in ABL1 or ABL2. Sensitivity to imatinib or dasatinib treatment was measured by reduction in colony formation in response to treatment. … (full text at CIViC)

PMID 26758680 · Testoni et al., 2016 · Open in CIViC

ActA level was measured in serum and plasma samples of 64/87 lung adenocarcinoma patients and 46/66 age- and gender-matched controls (ELISA). ActA Levels were higher in patients than in controls and w… (full text at CIViC)

PMID 26950277 · Hoda et al., 2016 · Open in CIViC

High expression of ACTL6A has been shown to be associated with resistance to cisplatin in multiple cancer types. In vitro experiments using A549 and H1299 lung cancer cell lines showed that overexpres… (full text at CIViC)

PMID 33408251 · Xiao et al., 2021 · Open in CIViC

ACTL6A plays a role in DNA damage repair by maintaining integrity of the SWI/SNF complex, and is associated with resistance to cisplatin. Results from cell viability and survival assays showed that tr… (full text at CIViC)

PMID 33408251 · Xiao et al., 2021 · Open in CIViC

Case report of a 74-year old woman with EGFR- and ALK-negative lung adenocarcinoma. FISH identified a deletion of 5'RET (FISH, indicating RET-gene rearrangement) and genomic testing confirmed a fusion… (full text at CIViC)

PMID 25982012 · Subbiah et al., 2015 · Open in CIViC

A 28 year-old patient with non-small cell lung cancer was found to harbor the EML4-ALK fusion using reverse transcription PCR. Treatment with 250mg crizotinib twice daily resulted in rapid improvement… (full text at CIViC)

PMID 20979473 · Choi et al., 2010 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing EML4-ALK fusion (a known sensitizing alteration to crizotinib) and an ALK C1156Y co-mutation demonstrated resistance to crizotinib treatment compared… (full text at CIViC)

PMID 20979473 · Choi et al., 2010 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing EML4-ALK fusion (a known sensitizing alteration to crizotinib) and an ALK F1174C co-mutation, demonstrated resistance to crizotinib treatment compare… (full text at CIViC)

PMID 24675041 · Friboulet et al., 2014 · Open in CIViC

In an in vitro study, a FL5.12 cell line expressing NPM1-ALK (a known sensitizing alteration to crizotinib) and an ALK F1174L co-mutation, demonstrated resistance to crizotinib treatment (IC50: 347.63… (full text at CIViC)

PMID 27009859 · Amin et al., 2016 · Open in CIViC

In a phase 2 study (NCT0093245), a stage IV non-small cell lung cancer patient with acquired crizotinib resistance harbored an EML4-ALK gene rearrangement (a known sensitizing alteration to crizotinib… (full text at CIViC)

PMID 24736079 · Ignatius Ou et al., 2014 · Open in CIViC

A patient with ALK-rearranged lung adenocarcinoma responded to crizotinib treatment and then had relapse. Biopsy was taken within half a month and total DNA was extracted from the sample. Exons 20-28,… (full text at CIViC)

PMID 22277784 · Katayama et al., 2012 · Open in CIViC

In a non-small cell lung cancer patient with acquired crizotinib resistance, the tumor had an ALK gene rearrangement and an ALK G1202R co-mutation. The ALK G1202R tumor was reported to be refractory t… (full text at CIViC)

PMID 23729361 · Gainor et al., 2013 · Open in CIViC

This study analyzed patients with non small cell lung cancer (NSCLC) who were positive for EML4-ALK fusions (ALK+) and progressed on crizotinib monotherapy. One ALK+ patient had a novel fusion between… (full text at CIViC)

PMID 22235099 · Doebele et al., 2012 · Open in CIViC

The NSCLC cell line MGH021-4, harboring SQSTM1-ALK G1269A, was 6 times more sensitive to ceritinib (80nM GI50) than crizotinib (500 nM) in proliferation assays and caused notable reductions in phospho… (full text at CIViC)

PMID 24675041 · Friboulet et al., 2014 · Open in CIViC

In a non-small cell lung cancer patient with acquired crizotinib resistance, the tumor had an ALK gene rearrangement and an ALK G1269A co-mutation. The ALK G1269A tumor was reported to be refractory t… (full text at CIViC)

PMID 23729361 · Gainor et al., 2013 · Open in CIViC

Analysis of 48 lung adenocarcinomas identified novel ALK mutations in six tumours, including S413N in the MAM1 domain, V597A in the MAM2, H694R in an undefined region, G881D in the glycine-rich domain… (full text at CIViC)

PMID 21847362 · Wang et al., 2011 · Open in CIViC

Analysis of 48 lung adenocarcinomas identified novel ALK mutations in six tumours, including S413N in the MAM1 domain, V597A in the MAM2, H694R in an undefined region, G881D in the glycine-rich domain… (full text at CIViC)

PMID 21847362 · Wang et al., 2011 · Open in CIViC

The I1171T mutation in ALK fusions was found in a NSCLC patient shown positive for ALK rearrangement via break apart FISH assay, who progressed after 8 months of crizotinib, and then progressed again … (full text at CIViC)

PMID 25228534 · Katayama et al., 2014 · Open in CIViC

A 51 year old female never-smoker was diagnosed with stage IV NSCLC with liver metastases. ALK rearrangement was verified via FISH. She was treated with crizotinib at 250 mg twice daily but discontinu… (full text at CIViC)

PMID 25736571 · Ou et al., 2015 · Open in CIViC

Case study describes a female (age 58) never-smoker presenting with stage IV NSCLC with an ALK rearrangement (confirmed by fish). Patient was treated with crizotinib (partial response) and alectinib (… (full text at CIViC)

PMID 25393796 · Ou et al., 2014 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing EML4-ALK fusion (a known sensitizing alteration to crizotinib) and an ALK L1152P co-mutation, demonstrated resistance to crizotinib treatment compare… (full text at CIViC)

PMID 24675041 · Friboulet et al., 2014 · Open in CIViC

In a patient who had metastatic anaplastic lymphoma kinase (ALK)-rearranged lung cancer, resistance to crizotinib developed because of a mutation in the ALK kinase domain. This mutation is predicted t… (full text at CIViC)

PMID 26698910 · Shaw et al., 2016 · Open in CIViC

In a metastatic EML4-ALK rearranged non-small cell lung carcinoma patient harboring ALK C1156Y (a known crizotinib resistance mutation) and ALK L1198F co-mutations, ALK L1198F was associated with rese… (full text at CIViC)

PMID 26698910 · Shaw et al., 2016 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing EML4-ALK fusion (a known sensitizing alteration to crizotinib) and an ALK L1198P co-mutation, demonstrated resistance to crizotinib treatment compare… (full text at CIViC)

PMID 21948233 · Heuckmann et al., 2011 · Open in CIViC

In a phase 1 clinical trial (NCT01283516) 130 patients with advanced cancers all harboring ALK alterations were treated with ceritinib. Of 114 NSCLC patients treated with at least 400 mg/daily ceriti… (full text at CIViC)

PMID 24670165 · Shaw et al., 2014 · Open in CIViC

In this phase II, open-label, single-arm trial, 276 patients with a histologically or cytologically confirmed diagnosis of metastatic non-small-cell lung cancer that carried either an ALK or ROS1 gene… (full text at CIViC)

PMID 30413378 · Solomon et al., 2018 · Open in CIViC

In an in vitro study, a FL5.12 cell line expressing NPM1-ALK (a known sensitizing alteration to crizotinib) and an ALK R1192P co-mutation, demonstrated resistance to crizotinib treatment (IC50: 421.5 … (full text at CIViC)

PMID 27009859 · Amin et al., 2016 · Open in CIViC

In a prospective study (NCT01283516) of 130 cancer patients, a non-small cell lung cancer patient harboring a S1206Y mutation in the ALK portion of the ALK rearrangement was associated with a 60% resp… (full text at CIViC)

PMID 24670165 · Shaw et al., 2014 · Open in CIViC

In one patient with S214C mutation, the use of sorafenib has led to more than 5 years of survival and near remission.

PMID 24569458 · Imielinski et al., 2014 · Open in CIViC

Sorafenib can inhibit ARF-mediated MEK phosphorylation and soft agar colony formation of AALE cells expressing ARAF S214C in vitro.

PMID 24569458 · Imielinski et al., 2014 · Open in CIViC

Five patients with acquired resistance to crizotinib showed high concentration of amphiregulin in malignant pleural effusions.

PMID 23344087 · Kim et al., 2013 · Open in CIViC

A cell line (DFCI076) with EML1-ALK fusion and resistance mutation L1152R showed no response to ALK inhibition with crizotinib or TAE684. There was co-dependancy on AKT and EGFR-signaling and inhibiti… (full text at CIViC)

PMID 21791641 · Sasaki et al., 2011 · Open in CIViC

Bi-allelic Atm deletion in mouse models of Kras-mutant lung adenocarcinoma does not affect cisplatin responses. In marked contrast, Atm-deficient tumors displayed an enhanced response to the topoisome… (full text at CIViC)

PMID 28363999 · Schmitt et al., 2017 · Open in CIViC